NJ Bio, Inc. enters into a global license and assignment agreement with Aarvik Therapeutics Inc., to develop next-generation ADCs using their novel class of payloads and Aarvik’s innovative therapeutic antibodies.

In the recently finalized agreement, Aarvik Therapeutics acquired exclusive license to commercialize the novel proprietary payloads designed by NJ Bio for cancer therapy. Aarvik’s proprietary modular platform to develop molecules with improved therapeutic index backed by NJ Bio’s extensive expertise in chemistry and bioconjugations will help create transformational therapy for oncology.

Read more about this collaboration…

————-For more news and events, click here